Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Merck Sharp + Dohme Corp.

Pharmacopeia Inc.

Jocelyn Rivera

Viyyoor Moopil Girijavallabhan

Ronald J Doll

Timothy J Guzi

Alan K Mallams

Kamil Paruch

Lawrence Wayne Dillard

Michael P Dwyer

Vincent Stewart Madison

Douglas Walsh Hobbs

Thierry Olivier Fischmann

Carmen S Alvarez

Kartik M Keertikar

Vinh D Tran

Ray Anthony James

Haengsoon Park

Anil K Saksena

Yi-Tsung Liu

Vidyadhar Madhav Paradkar

Tin-Yau Chan

Jonathan A Pachter

Zhen Min He

Tin Yau Chan

Zhenmin He

Paul Kirschmeier

Vidyadhar M Hobbs

Rajat Bannerji

In its many embodiments, the present invention provides a method of inhibiting one or more cyclin dependent kinases in a patient comprising administering to said patient a therapeutically effective amount of at least one pyrazolo[1,5-a]pyrimidine compound or a pharmaceutical composition comprising such compound, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. An example pyrazolo[1,5-a]pyrimidine compound useful in the present invention is shown below: 

Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors

There are disclosed compounds of the formula (I): prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17&#x3b2;-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.

17&#x3b2;-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

17 &#x3b2;-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

There are disclosed compounds of the formula (I):prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17&#x3b2;-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.

Growing community of inventors

Monmouth Junction, NJ, United States of America

Jocelyn Rivera